SNDX vs. VKTX, TGTX, KRYS, AXSM, OGN, SRRK, ALVO, RARE, ADMA, and VRNA
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Axsome Therapeutics (AXSM), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Syndax Pharmaceuticals vs.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
Syndax Pharmaceuticals currently has a consensus price target of $36.20, suggesting a potential upside of 176.76%. Viking Therapeutics has a consensus price target of $106.75, suggesting a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Syndax Pharmaceuticals.
Viking Therapeutics received 234 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 65.37% of users gave Syndax Pharmaceuticals an outperform vote.
Syndax Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Viking Therapeutics' return on equity of -12.73% beat Syndax Pharmaceuticals' return on equity.
In the previous week, Viking Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Viking Therapeutics and 9 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.42 beat Viking Therapeutics' score of 0.39 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
76.0% of Viking Therapeutics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Viking Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Syndax Pharmaceuticals on 14 of the 16 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SNDX) was last updated on 1/18/2025 by MarketBeat.com Staff
